WHO classification of tumours of the central nervous system

By D. Louis. 2007

3,747 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/895ba2d6b9c6eae6d61c48e842a57d05e95b42c8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS) (2015, background): “aggressive form of the disease, classified as high-grade gliomas, have a median survival rate of two years or less and require immediate treatment [2], [3].”
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. (2009, methodology): “All tumors were classified according to the WHO classification of tumors of the CNS.14-15 Essential characteristics including the presence or absence of necrosis, pseudopalisading perinecrotic cells, microvascular proliferation, giant cells, oligodendroglial-like, sarcomatous, neuronal or other comp”
DNA methylation-based classification of central nervous system tumours (2018, unknown): “To establish a comprehensive CNS tumour reference cohort, we generated genome-wide DNA methylation profiles (minimum of eight cases per group) representing almost all WHO defined neuroectodermal and sellar region tumours 1 .”
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas (2008, unknown): “They are not usually infiltrating, with malignancy grade 1 in the WHO classification (2), and progression to higher grades is extremely rare.”
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas (2009, methodology): “All tumors were diagnosed and classified according to the WHO classification of tumors of the nervous system [12].”
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. (2014, background): “If neither RT nor alkylating agents are options because they failed or because of intolerance, bevacizumab can be considered as a salvage strategy, depending on local availability.(11,13,20,21) Proper controlled studies are lacking here, however, and there is also no evidence to combine bevacizumab ”